These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 8442093)

  • 21. Unexpected T-cell diversity in syngeneic graft-versus-host disease revealed by interaction with peptide-loaded soluble MHC class II molecules.
    Hess AD; Thoburn CJ; Chen W; Bright AE
    Transplantation; 2003 Apr; 75(8):1361-7. PubMed ID: 12717231
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Donor antigen-presenting cells regulate T-cell expansion and antitumor activity after allogeneic bone marrow transplantation.
    Li JM; Waller EK
    Biol Blood Marrow Transplant; 2004 Aug; 10(8):540-51. PubMed ID: 15282532
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cytokine expression in human cutaneous chronic graft-versus-host disease.
    Ochs LA; Blazar BR; Roy J; Rest EB; Weisdorf DJ
    Bone Marrow Transplant; 1996 Jun; 17(6):1085-92. PubMed ID: 8807119
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Xenogeneic graft-versus-host disease is associated with elevated levels of reactive nitrogen intermediates.
    Cooper MH; Hoffman RA; Jacob TD; Nalesnik MA; DiSilvio M; Ildstad ST
    Transplant Proc; 1992 Dec; 24(6):2872-3. PubMed ID: 1465978
    [No Abstract]   [Full Text] [Related]  

  • 25. Selective inhibition of CD4 graft-versus-host activity in IL-2-treated mice.
    Sykes M; Abraham VS; Harty MW; Pearson DA
    Transplant Proc; 1993 Feb; 25(1 Pt 2):1225-6. PubMed ID: 8442096
    [No Abstract]   [Full Text] [Related]  

  • 26. Oral tolerization ameliorates liver disorders associated with chronic graft versus host disease in mice.
    Nagler A; Pines M; Abadi U; Pappo O; Zeira M; Rabbani E; Engelhardt D; Ohana M; Chowdhury NR; Chowdhury JR; Ilan Y
    Hepatology; 2000 Mar; 31(3):641-8. PubMed ID: 10706554
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cytolytic effector mechanisms and gene expression in autologous graft-versus-host disease: distinct roles of perforin and Fas ligand.
    Miura Y; Thoburn CJ; Bright EC; Hess AD
    Biol Blood Marrow Transplant; 2004 Mar; 10(3):156-70. PubMed ID: 14993881
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Donor CD4+ T-cell production of tumor necrosis factor alpha significantly contributes to the early proinflammatory events of graft-versus-host disease.
    Ewing P; Miklos S; Olkiewicz KM; Müller G; Andreesen R; Holler E; Cooke KR; Hildebrandt GC
    Exp Hematol; 2007 Jan; 35(1):155-63. PubMed ID: 17198884
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sequential analysis by polymerase chain reaction of mononuclear leukocyte activation-associated transcription in pancreatic islet cell allograft rejection.
    O'Connell PJ; Pacheco-Silva A; Bastos M; Xu HW; Pankewycz O; Rubin-Kelley VE; Strom TB
    Transplant Proc; 1991 Feb; 23(1 Pt 1):811-2. PubMed ID: 1990697
    [No Abstract]   [Full Text] [Related]  

  • 30. Cytokines other than growth factors in bone marrow transplantation.
    Ferrara JL
    Curr Opin Oncol; 1994 Mar; 6(2):127-34. PubMed ID: 7516711
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An epithelial target site in experimental graft-versus-host disease and cytokine-mediated cytotoxicity is defined by cytokeratin 15 expression.
    Whitaker-Menezes D; Jones SC; Friedman TM; Korngold R; Murphy GF
    Biol Blood Marrow Transplant; 2003 Sep; 9(9):559-70. PubMed ID: 14506658
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cytokine inhibitors and graft-versus-host disease.
    Ferrara JL
    Ann N Y Acad Sci; 1995 Dec; 770():227-36. PubMed ID: 8597363
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Why is graft-versus-host disease sometimes associated with leukoderma and fewer melanocytic naevi?
    Feily A; Namazi MR
    J Cosmet Dermatol; 2010 Mar; 9(1):64-5. PubMed ID: 20367675
    [No Abstract]   [Full Text] [Related]  

  • 34. Xenoreactivity in mouse + rat-->mouse chimeras.
    Conrad BG; Wren SM; Thai NL; Wang SC; Ricordi C; Fung JJ; Perry FE; Ildstad ST
    Transplant Proc; 1993 Feb; 25(1 Pt 1):455-6. PubMed ID: 8438377
    [No Abstract]   [Full Text] [Related]  

  • 35. [Capacity of regenerated spleen cells to accomplish a graft-versus-host reaction].
    Kharlova GV; Bliakher MS; Gambarov SS
    Biull Eksp Biol Med; 1976 Mar; 81(3):373-4. PubMed ID: 8175
    [No Abstract]   [Full Text] [Related]  

  • 36. Effects of interleukin 2 on leukemia development after bone marrow transplantation in AKR/J mice.
    Hashino S; Imamura M; Zhu X; Imai K; Kobayashi S; Tanaka J; Fujii Y; Kasai M; Miyazaki T
    Transplantation; 1995 Jun; 59(11):1642-5. PubMed ID: 7778185
    [No Abstract]   [Full Text] [Related]  

  • 37. Cytokines and graft-V-host disease.
    Antin JH
    Prog Clin Biol Res; 1994; 390():193-202. PubMed ID: 7724646
    [No Abstract]   [Full Text] [Related]  

  • 38. Immune reconstitution post-bone marrow transplantation.
    Gelfand EW
    Int J Cell Cloning; 1986; 4 Suppl 1():19-25. PubMed ID: 3528331
    [No Abstract]   [Full Text] [Related]  

  • 39. Paradigm shift for graft-versus-host disease.
    Ferrara JL
    Bone Marrow Transplant; 1994 Aug; 14(2):183-4. PubMed ID: 7994229
    [No Abstract]   [Full Text] [Related]  

  • 40. Inductive effects of immunological cytokines in the skin.
    Sauder DN
    Immunol Ser; 1989; 46():97-108. PubMed ID: 2484958
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.